Caplight Directory>Companies>ImmunoVec-preview>Immunovec


ImmunoVec

ImmunoVec

Private
Los Angeles, CaliforniaN/Ahttps://immunovec.com/

Last Round

Series A

Oct 8, 2025

Total Funding Raised

$56.55M

Company Overview

ImmunoVec is a biotechnology company developing a platform for in-vivo cell engineering to create therapies for autoimmune diseases, solid tumors, and genetic disorders.

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunoVec Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ImmunoVec Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AOct 8, 2025
GrantOct 8, 2025
GrantMay 29, 2025
SeedMar 2, 2022
GrantDec 2, 2021
Grant
May 1, 2016
View all Funding Rounds

Key People

Founding team and executive leadership

Ryan Wong

Chief Executive Officer

Executive Team

Feiyang Ma

Chief Technology Officer

Executive Team

ImmunoVec Investors

Notable investors and investment history

InvestorRounds
Constellar VenturesSeed
California Institute for Regenerative MedicineGrant
Anthem Venture PartnersSeed, Series A
ARPA-HGrant
Onelin Capital CorporationSeed
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 8, 2025

    $41M grant awarded by ARPA-H

  • Oct 8, 2025

    Raised Series A with Anthem Venture Partners

View all signals

ImmunoVec Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImmunoVec Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmunoVec's valuation, stock price, and market status.

Firmographic Details

HeadquartersLos Angeles, California
Employee Range11
Year Founded2020
Last FundingOct 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.